@inbook{ef192c6fa9dc4011ac34372930e31d42,
title = "Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach",
abstract = "Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related mortality worldwide and 80%–90% of HCC develops in patients that have underlying cirrhosis. Better methods of surveillance are needed to increase early detection of HCC and the proportion of patients that can be offered curative therapies. Recent work in novel mass spec-based methods for glycomic and glycopeptide analysis for discovery and confirmation of markers for early detection of HCC versus cirrhosis is reviewed in this chapter. Results from recent work in these fields by several groups and the progress made in developing markers of early HCC which can outperform the current serum-based markers are described and discussed. Also, recent developments in isoform analysis of glycans and glycopeptides and in various mass spec fragmentation methods will be described and discussed.",
keywords = "Biomarker, Glycomics, Glycoproteomics, Liver diseases, Mass spectrometry",
author = "Yehia Mechref and Wenjing Peng and Sakshi Gautam and Parisa Ahmadi and Yu Lin and Jianhui Zhu and Jie Zhang and Suyu Liu and Singal, {Amit G.} and Parikh, {Neehar D.} and Lubman, {David M.}",
note = "Funding Information: We acknowledge the support of this work from the National Cancer Institute under grants 1R01 CA160254 (DML) and U01 CA225753 (DML/YM). We also acknowledge the support of this work from the National Institutes of Health under grants 1R01GM112490(YM) and 1R01GM130091(YM). The Orbitrap instrument was purchased under an NIH shared instrumentation grant S10OD021619. Dr. Singal acknowledges the support from the National Cancer Institute under grant U01 CA230694 (AGS). DML acknowledges support under the Maud T. Lane Professorship. We also acknowledge the support of this work from Protein Metrics Inc for the use of the Byonic/Byologic software. Funding Information: We acknowledge the support of this work from the National Cancer Institute under grants 1R01 CA160254 (DML) and U01 CA225753 (DML/YM). We also acknowledge the support of this work from the National Institutes of Health under grants 1R01GM112490(YM) and 1R01GM130091(YM) . The Orbitrap instrument was purchased under an NIH shared instrumentation grant S10OD021619 . Dr. Singal acknowledges the support from the National Cancer Institute under grant U01 CA230694 (AGS). DML acknowledges support under the Maud T. Lane Professorship. We also acknowledge the support of this work from Protein Metrics Inc for the use of the Byonic/Byologic software. Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",
year = "2022",
doi = "10.1016/bs.acr.2022.07.005",
language = "English (US)",
series = "Advances in Cancer Research",
publisher = "Academic Press Inc.",
booktitle = "Advances in Cancer Research",
}